ClinicalTrials.gg
CompletedNCT01515865Updated Jun 9, 2021Results posted

Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

A Phase 4 interventional study of Midodrine HCl and Placebo in Symptomatic Orthostatic Hypotension, sponsored by Shire. Completed at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing midodrine in Hypotension, Orthostatic — none open to participants now, none under way, none of them phase 3. Midodrine · Hypotension, Orthostatic.

Enrollment
6th of 16
98 · median 42
Started
2012
with 2 others
Phase 4
6 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
5 of 16
Shire

Among the 16 studies testing midodrine in Hypotension, Orthostatic, this one is the 6th largest by enrollment, is one of 3 that started in 2012, is one of 6 in phase 4, and was the 8th registered.

Hypotension, Orthostatic

159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.

Browse Hypotension, Orthostatic studies →

Open to participants now

None of the 16 studies testing midodrine in Hypotension, Orthostatic is open now. The open studies under Hypotension, Orthostatic, anywhere →

About midodrine

Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing midodrine in Hypotension, Orthostatic as a file.
02

Study summary

To study the effect of midodrine against the symptoms of orthostatic hypotension

Read the detailed description

The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 9 overnight stays.

03

Conditions studied

  • Symptomatic Orthostatic Hypotension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects must be 18 years of age or older and ambulatory.
  2. Females of (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.
  3. A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl, and has been at a stable dose for at least 3 months.
  4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.

Exclusion criteria

Exclusion criteria

  1. The subject is a pregnant or lactating female.
  2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.
  3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.
  4. The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be
  5. The subject has participated in other studies of drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).
  6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.
  8. Known or suspected intolerance or to the investigational product(s), closely-related compounds, or any of the stated ingredients.
  9. Prior enrollment failure or randomization in this study.
  10. History of alcohol abuse or other substance abuse within the last year.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Midodrine HCl

    Drug: Midodrine HCl

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • dose at subject's current dose level

    Also known as: ProAmatine®

  • DrugPlacebo

    single dose of matching placebo

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Failed to Maintain a Response

    Failure to maintain a response was defined as any randomized subject that met both criterion 1 and criterion 2 below on Day 16: 1. The Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score increased by \>=4 points compared to baseline. OHSA Item 1 is a dizziness scale that is scored on a range from 0 (no dizziness) to 10 (severe dizziness). A lower score indicates less severe symptoms. 2. There was an increase in the number of syncopal/near syncopal events or severity of events within 15 minutes of standing compared to those observed at baseline. Syncope was defined as a loss of consciousness, and near syncope was defined as a feeling (e.g., dizziness, lightheadedness, feeling faint, feeling as though one would black out) that, without intervention, would lead to a loss of consciousness.

    Time frame: 30 minutes post-dose on Day 16

07

Results

Posted Oct 22, 2014

Participant flow

Part A (Open-label)
Participant flow — Part A (Open-label)
MilestoneMidodrine HCl - (Open-label)Midodrine HCl - (Randomized)Placebo - (Randomized)
Started9800
Completed9500
Not completed300
Withdrew: Other300
Part B (Open-label)
Participant flow — Part B (Open-label)
MilestoneMidodrine HCl - (Open-label)Midodrine HCl - (Randomized)Placebo - (Randomized)
Started7100
Completed6900
Not completed200
Withdrew: Withdrawal by subject100
Withdrew: Other100
Part C (Randomized)
Participant flow — Part C (Randomized)
MilestoneMidodrine HCl - (Open-label)Midodrine HCl - (Randomized)Placebo - (Randomized)
Started03334
Completed03334
Not completed000

Outcome measures

PrimaryPercent of Subjects Who Failed to Maintain a Response

Failure to maintain a response was defined as any randomized subject that met both criterion 1 and criterion 2 below on Day 16: 1. The Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score increased by \>=4 points compared to baseline. OHSA Item 1 is a dizziness scale that is scored on a range from 0 (no dizziness) to 10 (severe dizziness). A lower score indicates less severe symptoms. 2. There was an increase in the number of syncopal/near syncopal events or severity of events within 15 minutes of standing compared to those observed at baseline. Syncope was defined as a loss of consciousness, and near syncope was defined as a feeling (e.g., dizziness, lightheadedness, feeling faint, feeling as though one would black out) that, without intervention, would lead to a loss of consciousness.

Time frame:
30 minutes post-dose on Day 16
Reported as:
Number · percentage of participants
Percent of Subjects Who Failed to Maintain a Response
percentage of participantsMidodrine HClPlacebo
Percent of Subjects Who Failed to Maintain a Response30.344.1
Statistical analysis
  • Midodrine HCl vs Placebo · Fisher Exact · p = 0.3145 · Mean difference (final values): -13.8 · 95% CI -37.6 to 9.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midodrine HCl - Open-label (Part A)—0/98 (0%)5/98 (5.1%)
Midodrine HCl - Open-label (Part B)—0/71 (0%)2/71 (2.8%)
Midodrine HCl - Randomized (Part C)—0/33 (0%)0/33 (0%)
Placebo - Randomized (Part C)—0/34 (0%)0/34 (0%)
Most frequent other events
Most frequent other events
EventMidodrine HCl - Open-label (Part A)Midodrine HCl - Open-label (Part B)Midodrine HCl - Randomized (Part C)Placebo - Randomized (Part C)
HeadacheNervous system disorders5/982/710/330/34

Baseline characteristics

The Enrolled Population consisted of all subjects who participated in Part A baseline procedures starting at Day -1.

Age, Continuous
Age, Continuous(years)Enrolled Population
Mean45.5 ± 17.45
Sex: Female, Male
Sex: Female, Male(Participants)Enrolled Population
Female76
Male22
Region of Enrollment
Region of Enrollment(Participants)Enrolled Population
United States90
Slovakia3
Poland5
08

Study locations

32 sites
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Pharmaseek-Burbank
    North Hollywood, California 91606, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • Advance Research Institute Inc
    New Port Richey, Florida 34653, United States
  • DMI Reasearch Inc
    Pinellas Park, Florida 33782, United States
  • Parkinson's Disease Treatment Center of Southwest Florida
    Port Charlotte, Florida 33980, United States
  • Chicago Medical VA
    North Chicago, Illinois 60064, United States
  • Analab Clinical Research Inc
    Lenexa, Kansas 66219, United States
  • PAREXEL International - Baltimore EPCU Harbor Hospital
    Baltimore, Maryland 21225, United States
  • Frontage Clinical Services
    Hackensack, New Jersey 07601, United States
  • Buffalo Clinical Research Center (BCRC)
    Buffalo, New York 14202, United States
  • Columbia University
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Kidney and Hypertension Center
    Roseburg, Oregon 97471, United States
  • New Orleans Center for Clinical Research - Knoxville
    Knoxville, Tennessee 37920, United States
  • UT South West Medical Center
    Dallas, Texas 75390, United States
  • The Heartbeat Clinic, PA
    McKinney, Texas 75069, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • Fakultní nemocnice Hradec Králové
    Hradec, Králové 500 05, Czechia
  • Fakultní nemocnice Ostrava
    Ostrava, Poruba 708 52, Czechia
  • Fakultní nemocnice v Motole
    Praha, 150 06, Czechia
  • EMC Silesia Sp. z o.o.; NZOZ Szpital Geriatryczny im. Jana Pawła II w Katowicach
    Katowice, 40-353, Poland
  • Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, + satelite site:NZOZ Szpital Avimed Sp. z o.o.
    Katowice, 40-588, Poland
  • Centrum Medyczne HCP, Lecznictwo Stacjonarne, Oddział Udarowy
    Poznań, 61-485, Poland
  • MTZ Clinical Research Sp. z o.o.
    Warszawa, 02-106, Poland
  • Wojskowy Instytut Medyczny, Klinika Neurologiczna
    Warszawa, 04-141, Poland
  • Neurologická klinika SZU a UNB, Univerzitná nemocnica Bratislava
    Bratislava, 826 06, Slovakia
  • Neurologická klinika UN Martin, Univerzitná nemocnica Martin
    Martin, 036 59, Slovakia
  • Neurologická klinika FN Nitra, Fakultná nemocnica Nitra
    Nitra, 949 01, Slovakia
  • Neurologické oddelenie, Nemocnica s poliklinikou Spišská Nová Ves, a.s.
    Spišská Nová Ves, 052 01, Slovakia
  • Neurologické oddelenie FN Trnava, Fakultná nemocnica Trnava
    Trnava, 917 75, Slovakia
  • Neurologické oddelenie FNsP Žilina, Fakultná nemocnica s poliklinikou Žilina
    Žilina, 012 07, Slovakia
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2012 to primary completion in Nov 2013, 17 months.

Results were first posted in Oct 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2012
First posted
Jan 24, 2012
StartActual
May 23, 2012
Primary completionActual
Nov 11, 2013
CompletionActual
Nov 11, 2013
Results first posted
Oct 22, 2014
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01515865
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
May 23, 2012
Primary completion
Nov 11, 2013
Completion
Nov 11, 2013
Results posted
Oct 22, 2014
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midodrine

Start the discussion